logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Acute Myelogenous Leukemia Genetics Biology And Therapy 1st Edition Zeev Estrov Auth

  • SKU: BELL-4389460
Acute Myelogenous Leukemia Genetics Biology And Therapy 1st Edition Zeev Estrov Auth
$ 31.00 $ 45.00 (-31%)

0.0

0 reviews

Acute Myelogenous Leukemia Genetics Biology And Therapy 1st Edition Zeev Estrov Auth instant download after payment.

Publisher: Springer-Verlag New York
File Extension: PDF
File size: 3.82 MB
Pages: 280
Author: Zeev Estrov (auth.), Lalitha Nagarajan (eds.)
ISBN: 9780387692579, 9780387692593, 0387692576, 0387692592
Language: English
Year: 2010
Edition: 1

Product desciption

Acute Myelogenous Leukemia Genetics Biology And Therapy 1st Edition Zeev Estrov Auth by Zeev Estrov (auth.), Lalitha Nagarajan (eds.) 9780387692579, 9780387692593, 0387692576, 0387692592 instant download after payment.

Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages.

Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.

"The effective treatment of acute myelogenous leukemia remains a great challenge. This text reviews our understanding of the molecular and biologic basis of the disease. Leading investigators address advances in prognostication and therapeutic strategies that have significant promise."
Steven T. Rosen, M.D.
Series Editor

Related Products